Rezolute (NASDAQ:RZLT) Given “Buy” Rating at HC Wainwright

Rezolute (NASDAQ:RZLT)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 154.55% from the company’s previous close.

Separately, Wedbush reissued an “outperform” rating and set a $112.00 target price on shares of Rezolute in a research note on Monday, November 4th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Rezolute has an average rating of “Buy” and a consensus target price of $24.13.

Rezolute Trading Up 5.0 %

Shares of NASDAQ:RZLT opened at $5.50 on Wednesday. The company has a market capitalization of $318.67 million, a price-to-earnings ratio of -4.33 and a beta of 1.10. Rezolute has a 12 month low of $0.92 and a 12 month high of $6.19. The firm’s 50-day moving average is $4.89 and its 200 day moving average is $4.88.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.13. As a group, equities analysts forecast that Rezolute will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling at Rezolute

In related news, CFO Daron Evans bought 9,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $4.60 per share, with a total value of $41,400.00. Following the transaction, the chief financial officer now owns 140,900 shares of the company’s stock, valued at $648,140. The trade was a 6.82 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 18.39% of the company’s stock.

Institutional Investors Weigh In On Rezolute

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Rezolute by 39.0% in the 3rd quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock worth $2,385,000 after purchasing an additional 137,905 shares in the last quarter. Exome Asset Management LLC boosted its holdings in Rezolute by 24.7% in the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock worth $1,707,000 after acquiring an additional 69,656 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Rezolute during the second quarter worth about $255,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Rezolute during the third quarter valued at about $239,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of Rezolute by 366.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares during the last quarter. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.